

# KDDF

Establishing the system for developing more than 10 global drugs.



Ministry of Science, ICT and Future Planning



MOTIE  
MINISTRY OF  
TRADE, INDUSTRY & ENERGY



MINISTRY OF  
HEALTH & WELFARE

- A government-initiated drug development program (Total budget of \$1billion)
  - > Select, Fund and Manage Projects
- Backed by a collaborative effort of 3 healthcare-related Korea Ministries
- Three effective business models
  - > Novel & Innovative / Big pharma customized / Connect & Development

## Major Achievements

**Licensing Out: 14 (Deal Value: 4.5 billion USD)**

Global Licensing Out : 5 (Deal Value : 4.47 billion USD)

- Quirient (tuberculosis) >> Infectex (Russia)
- PharmAbcine (cancer) >> 3S BIO (China)
- Genexine (growth hormone) >> Tasgen (China)
- CJ HealthCare (acid related disorder) >> Luoxin (China)
- Hanmi (diabetes) >> Sanofi (France)

Domestic (Global Bridging) Licensing Out (Deal Value : 30 million USD)

- Genexine (growth hormone), Chungnam National Univ. (heart failure, blindness)
- SK Biopharm (constipation, IBS), PharmAbcine (eye related disease)
- Ajou Univ. (diabetic macular edema), Aeon Medix (*S. aureus* vaccine)
- Korea Univ. (duchenne muscular dystrophy), BIONEER (pulmonary fibrosis)

## R&D Performance



(R&D) 성과

